National Albuterol Shortage Has Been Resolved
The FDA declared the end of a long-term supply shortage after Ritedose expanded its manufacturing operations.
Updated on Sept. 24, 2026 in Asthma
Live Poll
Should the U.S. prioritize domestic manufacturing to prevent future essential medical supply shortages?
The U.S. Food and Drug Administration has officially declared the national albuterol inhalation solution shortage resolved. This milestone follows nearly four years of supply constraints that affected millions of patients nationwide.
Why it matters
The resolution of this shortage ensures that the 26 million Americans with asthma, including 7 million children, have reliable access to essential respiratory medications. Stabilized production helps mitigate the risk of supply disruptions that previously threatened patient care.
The FDA approved a new 2.5 mg/0.5 ml dosage in 2025 to bolster supply, supplementing existing 0.5% and 2.5 mg/3 mL formulations. These products support a patient population of 26 million people in the United States currently living with asthma.
The players
The Ritedose Corporation
This company specializes in sterile Blow-Fill-Seal manufacturing for pharmaceutical products and is based in Columbia, South Carolina.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
The details
Ritedose expanded its sterile Blow-Fill-Seal manufacturing capacity to address the national deficit. The company added a seventh Syntegon packaging line and opened a new logistics and distribution center at Performance Park in Columbia, South Carolina.
Timeline
The national albuterol inhalation solution shortage was declared in 2022.
The FDA approved the 2.5 mg/0.5 ml dosage in 2025.
Ritedose announced the expanded manufacturing capabilities and shortage resolution on September 24, 2026.
The Big Picture
This resolution officially ends the 2022 national albuterol inhalation solution shortage. The move signals a return to market stability after years of critical supply gaps that challenged medical providers and patients.
Patients can expect improved availability of essential albuterol inhalation solutions at pharmacies across the country. This stabilization helps ensure that asthma treatment plans remain uninterrupted by previous distribution bottlenecks.
The takeaway
Reliable access to medication is a cornerstone of effective long-term asthma management for millions of Americans. Patients should continue to work closely with their healthcare providers to maintain their prescribed dosage routines now that supply chains have stabilized.
Further reading
For additional context on respiratory care and management, visit the Asthma section.
More information
For more details on product specifications, visit Ritedose company and services information.
Live Poll
Should the U.S. prioritize domestic manufacturing to prevent future essential medical supply shortages?
